993 related articles for article (PubMed ID: 26377368)
1. Atomoxetine Treatment Strengthens an Anti-Correlated Relationship between Functional Brain Networks in Medication-Naïve Adults with Attention-Deficit Hyperactivity Disorder: A Randomized Double-Blind Placebo-Controlled Clinical Trial.
Lin HY; Gau SS
Int J Neuropsychopharmacol; 2015 Sep; 19(3):pyv094. PubMed ID: 26377368
[TBL] [Abstract][Full Text] [Related]
2. Neural correlates of atomoxetine improving inhibitory control and visual processing in Drug-naïve adults with attention-deficit/hyperactivity disorder.
Fan LY; Chou TL; Gau SS
Hum Brain Mapp; 2017 Oct; 38(10):4850-4864. PubMed ID: 28657141
[TBL] [Abstract][Full Text] [Related]
3. Atomoxetine Increased Effect over Time in Adults with Attention-Deficit/Hyperactivity Disorder Treated for up to 6 Months: Pooled Analysis of Two Double-Blind, Placebo-Controlled, Randomized Trials.
Wietecha LA; Clemow DB; Buchanan AS; Young JL; Sarkis EH; Findling RL
CNS Neurosci Ther; 2016 Jul; 22(7):546-57. PubMed ID: 26922462
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of methylphenidate and atomoxetine on intrinsic brain activity in children with attention deficit hyperactivity disorder.
Shang CY; Yan CG; Lin HY; Tseng WY; Castellanos FX; Gau SS
Psychol Med; 2016 Nov; 46(15):3173-3185. PubMed ID: 27574878
[TBL] [Abstract][Full Text] [Related]
5. Attention network hypoconnectivity with default and affective network hyperconnectivity in adults diagnosed with attention-deficit/hyperactivity disorder in childhood.
McCarthy H; Skokauskas N; Mulligan A; Donohoe G; Mullins D; Kelly J; Johnson K; Fagan A; Gill M; Meaney J; Frodl T
JAMA Psychiatry; 2013 Dec; 70(12):1329-37. PubMed ID: 24132732
[TBL] [Abstract][Full Text] [Related]
6. Differential therapeutic effects of 12-week treatment of atomoxetine and methylphenidate on drug-naïve children with attention deficit/hyperactivity disorder: A counting Stroop functional MRI study.
Chou TL; Chia S; Shang CY; Gau SS
Eur Neuropsychopharmacol; 2015 Dec; 25(12):2300-10. PubMed ID: 26409297
[TBL] [Abstract][Full Text] [Related]
7. Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial.
Durell TM; Adler LA; Williams DW; Deldar A; McGough JJ; Glaser PE; Rubin RL; Pigott TA; Sarkis EH; Fox BK
J Clin Psychopharmacol; 2013 Feb; 33(1):45-54. PubMed ID: 23277268
[TBL] [Abstract][Full Text] [Related]
8. Effect of Atomoxetine Treatment on Reading and Phonological Skills in Children with Dyslexia or Attention-Deficit/Hyperactivity Disorder and Comorbid Dyslexia in a Randomized, Placebo-Controlled Trial.
Shaywitz S; Shaywitz B; Wietecha L; Wigal S; McBurnett K; Williams D; Kronenberger WG; Hooper SR
J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):19-28. PubMed ID: 27410907
[TBL] [Abstract][Full Text] [Related]
9. Methylphenidate and atomoxetine normalise fronto-parietal underactivation during sustained attention in ADHD adolescents.
Kowalczyk OS; Cubillo AI; Smith A; Barrett N; Giampietro V; Brammer M; Simmons A; Rubia K
Eur Neuropsychopharmacol; 2019 Oct; 29(10):1102-1116. PubMed ID: 31358436
[TBL] [Abstract][Full Text] [Related]
10. Atomoxetine could improve intra-individual variability in drug-naïve adults with attention-deficit/hyperactivity disorder comparably with methylphenidate: A head-to-head randomized clinical trial.
Ni HC; Hwang Gu SL; Lin HY; Lin YJ; Yang LK; Huang HC; Gau SS
J Psychopharmacol; 2016 May; 30(5):459-67. PubMed ID: 26905919
[TBL] [Abstract][Full Text] [Related]
11. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.
Dittmann RW; Schacht A; Helsberg K; Schneider-Fresenius C; Lehmann M; Lehmkuhl G; Wehmeier PM
J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):97-110. PubMed ID: 21488751
[TBL] [Abstract][Full Text] [Related]
12. Neurofunctional effects of methylphenidate and atomoxetine in boys with attention-deficit/hyperactivity disorder during time discrimination.
Smith A; Cubillo A; Barrett N; Giampietro V; Simmons A; Brammer M; Rubia K
Biol Psychiatry; 2013 Oct; 74(8):615-22. PubMed ID: 23731741
[TBL] [Abstract][Full Text] [Related]
13. Neurophysiologic predictors of response to atomoxetine in young adults with attention deficit hyperactivity disorder: a pilot project.
Leuchter AF; McGough JJ; Korb AS; Hunter AM; Glaser PE; Deldar A; Durell TM; Cook IA
J Psychiatr Res; 2014 Jul; 54():11-8. PubMed ID: 24726639
[TBL] [Abstract][Full Text] [Related]
14. Altered intrinsic organisation of brain networks implicated in attentional processes in adult attention-deficit/hyperactivity disorder: a resting-state study of attention, default mode and salience network connectivity.
Sidlauskaite J; Sonuga-Barke E; Roeyers H; Wiersema JR
Eur Arch Psychiatry Clin Neurosci; 2016 Jun; 266(4):349-57. PubMed ID: 26260900
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity disorder.
Gau SS; Huang YS; Soong WT; Chou MC; Chou WJ; Shang CY; Tseng WL; Allen AJ; Lee P
J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):447-60. PubMed ID: 17822340
[TBL] [Abstract][Full Text] [Related]
16. Atomoxetine-Related Change in Sluggish Cognitive Tempo Is Partially Independent of Change in Attention-Deficit/Hyperactivity Disorder Inattentive Symptoms.
McBurnett K; Clemow D; Williams D; Villodas M; Wietecha L; Barkley R
J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):38-42. PubMed ID: 27845858
[TBL] [Abstract][Full Text] [Related]
17. Shared and drug-specific effects of atomoxetine and methylphenidate on inhibitory brain dysfunction in medication-naive ADHD boys.
Cubillo A; Smith AB; Barrett N; Giampietro V; Brammer MJ; Simmons A; Rubia K
Cereb Cortex; 2014 Jan; 24(1):174-85. PubMed ID: 23048018
[TBL] [Abstract][Full Text] [Related]
18. A 1.5-Year Follow-Up of Parent Training and Atomoxetine for Attention-Deficit/Hyperactivity Disorder Symptoms and Noncompliant/Disruptive Behavior in Autism.
Arnold LE; Ober N; Aman MG; Handen B; Smith T; Pan X; Hyman SL; Hollway J; Lecavalier L; Page K; Rice R
J Child Adolesc Psychopharmacol; 2018 Jun; 28(5):322-330. PubMed ID: 29694241
[TBL] [Abstract][Full Text] [Related]
19. Altered social cognition and connectivity of default mode networks in the co-occurrence of autistic spectrum disorder and attention deficit hyperactivity disorder.
Wang K; Xu M; Ji Y; Zhang L; Du X; Li J; Luo Q; Li F
Aust N Z J Psychiatry; 2019 Aug; 53(8):760-771. PubMed ID: 30843728
[TBL] [Abstract][Full Text] [Related]
20. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder.
Harfterkamp M; van de Loo-Neus G; Minderaa RB; van der Gaag RJ; Escobar R; Schacht A; Pamulapati S; Buitelaar JK; Hoekstra PJ
J Am Acad Child Adolesc Psychiatry; 2012 Jul; 51(7):733-41. PubMed ID: 22721596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
